STUDresearch · Non-peptide
GT20029
Also known as
GT-20029 · GT 20029 · Kintor GT20029 · topical AR PROTAC · androgen receptor degrader topical · Kintor hair PROTAC
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Lots of talk
Local
Topical
Skin, hair & tissue remodeling
Local — a scalp liquid. Not a whole-body anti-androgen pill.
What people say
GT20029 is an investigational topical androgen-receptor PROTAC for androgenetic alopecia. The checked efficacy study used a formulated scalp spray; gray-market powder identity is a separate, unresolved risk.
Doses people talk about
Each application was 1 mL, described as seven sprays in the paper. These are trial arms, not instructions for gray-market powder or homemade liquid.
How it may feel
Phase 1 abstracts recorded local rash, exfoliation, pruritus, dryness or pain depending on study and formulation. Forum discussion was mostly trial interpretation and identity concern rather than verified long-term self-use diaries.
Phase 2 arm0.5% topical, 1 mL once daily
One of the two arms with a statistically significant week-12 target-area hair-count difference from vehicle.
Phase 2 arm1.0% topical, 1 mL twice weekly
The other arm with a significant week-12 hair-count difference; schedule efficacy does not establish half-life.
Phase 2 arm1.0% topical, 1 mL once daily
Studied but without a statistically significant week-12 target-area hair-count difference from vehicle in this split.
Half-life & effect duration
- Half-life in the body
- Topical productNo settled estimate
- Felt duration people report
- Felt durationNo consistent verified self-use timeline reported
Cycles people discuss
The efficacy evidence is a 12-week trial block with 28 days of follow-up, not a multi-year maintenance record. Hair-loss communities discuss ongoing use, but verified maintenance data remain absent.
Timing
Reported topical habits favor evening scalp use to separate it from morning minoxidil; people describe allowing one product to dry before layering another. These are community routines, not an established preferred schedule.
Stacks
Minoxidil and finasteride/dutasteride appear in mechanism-based stack discussion, but the checked GT20029 study did not test those combinations and community debate does not establish combined safety or benefit.
Access talk
Anyone selling “GT20029 5%” on a peptide site is not Kintor’s trial product.
Watch for
Identity: Gray powder labeled GT20029 is not equivalent to Kintor’s studied topical formulations.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The reviewed human Phase 1 abstracts do not provide a usable numerical GT20029 half-life.
Plasma exposure and half-life were assessed, but most measurements were low or near/below a 1 pg/mL quantification limit and no half-life value was reported in the accessible abstracts.
Conference abstracts provide compressed methods and results, formulations differed between China and the US, and very low systemic exposure limits elimination estimation.
- EADV Congress 2023 abstracts — Phase I GT20029 topical studies in China and the United States (opens in a new tab)China abstract on pages 14–15 and US abstract on pages 38–39: topical exposure, plasma concentrations near/below quantification, and application-site adverse events.Conference abstracts rather than full peer-reviewed reports; compressed methods, differing formulations and no reported numerical half-life despite assessment.
Felt duration people report
No verified self-use felt-duration window was established for GT20029.
The human studies report application-site adverse events and week-12 hair endpoints; the reviewed forum thread primarily interprets trial results and questions gray-market identity rather than documenting verified longitudinal use.
Trial efficacy at 12 weeks is not a per-application felt duration, and anonymous discussion cannot verify compound identity, concentration or long-term experience.
- A randomized, double-blind, vehicle-controlled Phase II trial of topical GT20029 in male androgenetic alopecia (opens in a new tab)Methods and results: 180 Chinese men, six arms, 1 mL/seven-spray applications for 12 weeks with 28-day follow-up; significant week-12 hair-count differences for 0.5% once daily and 1.0% twice weekly.Short 12-week company-sponsored study in Chinese men; small arm sizes, no long-term maintenance evidence and no parent half-life result.
- Reddit r/tressless — GT20029 big Phase 2 update results (opens in a new tab)Post and comments interpreting the trial, debating the strength of the result and warning that gray-market products may not match the studied formulation.Discussion and secondary interpretation, not verified self-use; anonymous commenters, no product authentication and no longitudinal outcome assessment.
What people say
- Twice-weekly convenience lore: People like the idea of two scalp nights instead of a daily liquid. That arm was one of the cleaner ones; it is not proof daily 1% is worse forever. forumtrial
- Stack mental model: tressless comments treat it as stackable with minoxidil, fin/dut, KX-826, and (later) PP405 because the mechanisms do not collide on paper. No combo RCT. forum
- What talk does not prove: Restoring a Norwood 6, beating oral dutasteride, or matching a transplant. 12-week Phase 2 is the whole public efficacy story so far. forum
- Hair-count charts: 0.5% once daily ~+16.8 vs +10.1 hairs/cm² placebo at week 12; 1.0% twice weekly ~+11.9 vs +4.6. Net ~7 hairs/cm² in the better arms — the screenshot, not a miracle density bomb. trial
- Thickness signal: 1.0% twice weekly also moved hair width vs placebo in that short study. trial
- Null / messy arm: The 1.0% once-daily arm did not show a statistically significant target-area hair-count difference from vehicle at week 12. The small trial does not establish irritation or a PROTAC “sweet spot” as the explanation. trial
Doses people talk about
- 1.0% twice weekly: The other cleaner arm; also the thickness signal. Convenience is why this one is the screenshot. trialforum
- Gray-market liquids: Vendor 0.5%/1% dropper talk copies the trial. Identity of the powder is the first fight, not the percent. forum
- Framing: Trial percents and DIY milligrams — not a labeled drug, not medical advice. forum
- 0.5% once daily: One of the two cleaner Phase 2 arms. trial
- 1.0% once daily: Studied; did not clearly beat placebo in 12 weeks. Not a “more is better” chart. trial
How it may feel
- Weeks 6–12: The photo window in the Phase 2 chart. DIY gray-market logs are shorter and noisier. forum
- After the bottle: Trial was 12 weeks. Forums do not have a multi-year maintenance diary on verified GT20029. forum
- If nothing happens: People blame fake powder, concentration math, or expecting minoxidil-speed baby hairs in a month. anecdote
- Application-site tolerability: Phase 1 abstracts reported rash, exfoliation and pruritus in China and mild dryness, pain or pruritus in the US; systemic concentrations were usually low or near/below quantification. Short trials do not establish long-term systemic safety. trial
Around the dose
- Clock: Evening scalp, like other leave-on hair liquids, so it is not competing with morning min foam in the same hour. forum
- After: Let it dry. People who layer minoxidil usually wait rather than mix in the same dropper. forum
- Not a workout pin. This is a scalp leave-on. forum
Cycles people discuss
- Hair-cycle honesty: Androgenetics is usually framed as stay-on, like min/fin, not an 8-week blast. No long public maintenance RCT yet. forum
- Stack calendars: People talk adding it to an existing min/fin base rather than cycling off the base. forum
- Trial block: 12 weeks on the liquid. trial
Timing
- Local pitch: Designed not to be a daily oral anti-androgen. Blood-level arguments are still forum speculation. forum
- PK not quantifiable here: Phase 1 investigators assessed plasma exposure and half-life, but most GT20029 measurements were near or below a 1 pg/mL quantification limit and the reviewed abstracts reported no usable half-life value. trial
- Twice-weekly schedule: One 1.0% twice-weekly arm showed a week-12 hair-count signal, but a selected study schedule does not establish parent half-life, scalp residence time or androgen-receptor recovery time. trial
More on what it is
- What most people mean: The “new fin” topical on r/tressless — degrade the androgen receptor on the scalp instead of shutting down DHT everywhere. forum
- Why people search it: 2025–26 Phase 2 writeups plus “stack with PP405 / min / fin” threads. People who already hate oral 5-AR sides, or who want a different mechanism on the hairline. forum
- How discussion frames mechanism: DHT can still be made. The pitch is fewer androgen receptors left on the follicle to hear it. Different job than finasteride, RU-58841 (block), or PP405 (wake dormant follicles). forumtrial
- Not: Not finasteride, not dutasteride, not RU-58841, not pyrilutamide, not a SARM, not a peptide. forum
- What it is: Kintor’s topical PROTAC (proteolysis-targeting chimera) designed to tag androgen receptors for degradation. Research chemical / trial drug, not an approved hair medicine. trial
- Phase 2 people paste: 180 Chinese men, Hamilton-Norwood IIIv–V, 12 weeks, 0.5% or 1.0% once daily or twice weekly vs placebo. Cleanest placebo gaps were 0.5% once daily and 1.0% twice weekly. trial
Stacks
- + Minoxidil: The default add. Different job. forum
- + Finasteride / dutasteride: Lower DHT *and* degrade receptors — the “belt and suspenders” camp. forum
- + Pyrilutamide / RU-58841: Other topical AR stories; stacking two AR drugs is argued, not settled. forum
- + PP405: 2026 “new fin + new min” fantasy stack. No combo trial. forum
Access talk
- Anyone selling “GT20029 5%” on a peptide site is not Kintor’s trial product. forum
- Not a 503A compounding staple the way fin/min are. forum
- Not FDA-approved. Phase 2 China data; Phase 3 still the waiting room. trial
Storage notes
- DIY powder-in-ethanol/PG is the gray-market version — same mixing culture as RU-58841. Identity first. forum
- Light/heat: Treat it like other research scalp solutions: cool, dark, capped. forum
- Trial product was a finished topical, not a lyophilized peptide. trial
Watch for
- Scalp irritation / dryness from the vehicle, same family as other alcohol/PG topicals. forum
- Not proven systemic-zero. “It stays on the head” is the pitch, not a lifetime safety table. forum
- Identity: Gray powder labeled GT20029 is not equivalent to Kintor’s studied topical formulations. forum
- Not a SARM. Mixing this name with muscle SARMs is a search fail. forum
- Pregnancy / women: Anti-androgen scalp talk is mostly male AGA diaries; female-pattern logs are thin. forum
- 12-week data only for the public efficacy story. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.